There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zai Lab (ZLAB – Research Report), Alphatec Holdings (ATEC – Research Report) and HCA Healthcare (HCA – Research Report) with bullish sentiments.
Zai Lab (ZLAB)
Bank of America Securities analyst David Li reiterated a Buy rating on Zai Lab today and set a price target of $25.00. The company’s shares closed last Tuesday at $21.55.
According to TipRanks.com, Li is ranked #8526 out of 8848 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zai Lab with a $51.33 average price target, implying a 138.5% upside from current levels. In a report issued on May 9, Leerink Partners also reiterated a Buy rating on the stock with a $63.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Alphatec Holdings (ATEC)
In a report released yesterday, Vik Chopra from Wells Fargo maintained a Buy rating on Alphatec Holdings, with a price target of $26.00. The company’s shares closed last Tuesday at $10.87.
According to TipRanks.com, Chopra is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on Alphatec Holdings is a Strong Buy with an average price target of $23.17, which is a 107.4% upside from current levels. In a report issued on April 30, TD Cowen also maintained a Buy rating on the stock with a $22.50 price target.
HCA Healthcare (HCA)
Bank of America Securities analyst Kevin Fischbeck maintained a Buy rating on HCA Healthcare yesterday and set a price target of $378.00. The company’s shares closed last Tuesday at $320.50, close to its 52-week high of $335.83.
According to TipRanks.com, Fischbeck is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for HCA Healthcare with a $351.46 average price target, which is a 10.5% upside from current levels. In a report released yesterday, DBS also initiated coverage with a Buy rating on the stock with a $370.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ZLAB:
- Zai Lab announces China NMPA approval for Augtyro NDA
- Zai Lab reports Q1 EPS (5c) , consensus (92c)
- Zai Lab files automatic ordinary shares offering
- Executive officers of Zai Lab ‘do not anticipate selling any shares’ in 2024
- Zai Lab, Bristol Myers: Krazati confirmatory trial meets PFS primary endpoints
